Suzanne Neppelenbroek

Treatment-specific risk of subsequent malignant neoplasms in five-year survivors of diffuse large B-cell lymphoma

Geurts, Y. M., Neppelenbroek, S. I. M., Aleman, B. M. P., Janus, C. P. M., Krol, A. D. G., van Spronsen, D. J., Plattel, W. J., Roesink, J. M., Verschueren, K. M. S., Zijlstra, J. M., Koene, H. R., Nijziel, M. R., Schimmel, E. C., de Jongh, E., Ong, F., te Boome, L. C. J., van Rijn, R. S., Böhmer, L. H., Ta, B. D. P., Visser, H. P. J., & 10 othersPosthuma, E. F. M., Bilgin, Y. M., Muller, K., van Kampen, D., So-Osman, C., Vermaat, J. S. P., de Weijer, R. J., Kersten, M. J., van Leeuwen, F. E. & Schaapveld, M., 1 Feb 2024, In: ESMO open. 9, 2, 102248.

Research output: Contribution to journal › Article › Academic › peer-review

Immune checkpoint inhibitor treatment and atherosclerotic cardiovascular disease: An emerging clinical problem

Poels, K., Neppelenbroek, S. I. M., Kersten, M. J., Antoni, M. L., Lutgens, E. & Seijkens, T. T. P., 24 Jun 2021, In: Journal for Immunotherapy of Cancer. 9, 6, e002916.

Research output: Contribution to journal › Review article › Academic › peer-review